Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

S. Bertolini, N. Elicio, A. Daga, M. L. Degl'Innocenti, R. Balestreri, M. G. Fusi, A. M. Cotta Ramusino, A. Carozzi

Research output: Contribution to journalArticle

Abstract

The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 1988

Fingerprint

Fenofibrate
Hyperlipoproteinemias
Lipoproteins
Therapeutics
Patient Compliance
Hyperlipidemias
Appointments and Schedules
Pharmacokinetics
Safety

Keywords

  • fenofibrate
  • hyperlipoproteinaemia
  • pharmacokinetics
  • plasma lipids
  • single daily dose

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. / Bertolini, S.; Elicio, N.; Daga, A.; Degl'Innocenti, M. L.; Balestreri, R.; Fusi, M. G.; Cotta Ramusino, A. M.; Carozzi, A.

In: European Journal of Clinical Pharmacology, Vol. 34, No. 1, 01.1988, p. 25-28.

Research output: Contribution to journalArticle

Bertolini, S, Elicio, N, Daga, A, Degl'Innocenti, ML, Balestreri, R, Fusi, MG, Cotta Ramusino, AM & Carozzi, A 1988, 'Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb', European Journal of Clinical Pharmacology, vol. 34, no. 1, pp. 25-28. https://doi.org/10.1007/BF01061412
Bertolini, S. ; Elicio, N. ; Daga, A. ; Degl'Innocenti, M. L. ; Balestreri, R. ; Fusi, M. G. ; Cotta Ramusino, A. M. ; Carozzi, A. / Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. In: European Journal of Clinical Pharmacology. 1988 ; Vol. 34, No. 1. pp. 25-28.
@article{c5c267fc7d8a443582fe080f9a109831,
title = "Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb",
abstract = "The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.",
keywords = "fenofibrate, hyperlipoproteinaemia, pharmacokinetics, plasma lipids, single daily dose",
author = "S. Bertolini and N. Elicio and A. Daga and Degl'Innocenti, {M. L.} and R. Balestreri and Fusi, {M. G.} and {Cotta Ramusino}, {A. M.} and A. Carozzi",
year = "1988",
month = "1",
doi = "10.1007/BF01061412",
language = "English",
volume = "34",
pages = "25--28",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

AU - Bertolini, S.

AU - Elicio, N.

AU - Daga, A.

AU - Degl'Innocenti, M. L.

AU - Balestreri, R.

AU - Fusi, M. G.

AU - Cotta Ramusino, A. M.

AU - Carozzi, A.

PY - 1988/1

Y1 - 1988/1

N2 - The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.

AB - The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.

KW - fenofibrate

KW - hyperlipoproteinaemia

KW - pharmacokinetics

KW - plasma lipids

KW - single daily dose

UR - http://www.scopus.com/inward/record.url?scp=0023851694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023851694&partnerID=8YFLogxK

U2 - 10.1007/BF01061412

DO - 10.1007/BF01061412

M3 - Article

C2 - 3282894

AN - SCOPUS:0023851694

VL - 34

SP - 25

EP - 28

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -